Vitiligo – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Vitiligo – Drugs In Development, 2024 report and make more profitable business decisions.
Vitiligo is a condition in which skin loses melanin, the pigment that determines the color of skin, hair, and eyes. Symptoms include premature whitening or graying of the hair on teh scalp, eyelashes, eyebrows, or beard; loss of color in the tissues that line the inside of mouth; and loss of or change in color of the inner layer of eye. Treatment includes corticosteroid therapy, immunomodulators, and surgery.
The Vitiligo drugs in development market research report provide comprehensive information on the therapeutics under development for Vitiligo, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vitiligo and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Vitiligo | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 43 molecules, with 41 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Vitiligo therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Vitiligo pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Vitiligo treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
2A Pharma ABAbbVie Inc
Ahammune Biosciences Pvt Ltd
Aldena Therapeutics Inc
Almirall SA
Amgen Inc
AnaptysBio Inc
AnTolRx Inc
AstraZeneca Plc
Avotres Inc
Beijing Puqi Pharmaceutical Technology Co Ltd
CAGE Biosciences Inc
Clinuvel Pharmaceuticals Ltd
Cour Pharmaceuticals Development Co Inc
E-nitiate Biopharmaceuticals (Hangzhou) Co Ltd
Edesa Biotech Inc
Elixiron Immunotherapeutics Inc
Forte Biosciences Inc
Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
HysensBio Corp
Incannex Healthcare Ltd
Incyte Corp
Jiangsu Hengrui Medicine Co Ltd
JN Biosciences LLC
Merck & Co Inc
National Research Council of Canada
Novartis AG
Ornovi Inc
Pfizer Inc
Radikal Therapeutics Inc
Shanghai Icure Biotechnology Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Sichuan Huiyu Pharmaceutical Co Ltd
Sinovant Sciences HK Ltd
Sirenas LLC
Technoderma Medicines Inc
Temprian Therapeutics Inc
TWi Biotechnology Inc
Villaris Therapeutics Inc
VYNE Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Vitiligo reports